Osteoporose Update

Die folgenden Publikationen sind nach dem Ende der systematischen Literaturrecherche für die Leitlinienaktualisierung publiziert worden. Die Abstracts wurden grafisch dargestellt ([Abb. 1], [2]).

Abb. 1 Abstract zu Leslie WD et al.

Abb. 2 Abstract zu Bhattoa HP et al.

Publikationsverlauf

Artikel online veröffentlicht:
14. November 2025

• Literatur

• 1 Pasco JA, Kotowicz MA, Henry MJ. et al. Statin use, bone mineral density, and fracture risk: Geelong osteoporosis study. Arch Intern Med 2002; 162: 537-540
• 2 Sirola J, Sirola J, Honkanen R. et al. Relation of statin use and bone loss: a prospective population-based cohort study in early postmenopausal women. Osteoporos Int 2002; 13: 537-541
• 3 LaCroix AZ, Cauley JA, Pettinger M. et al. Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative observational study. Ann Intern Med 2003; 139: 97-104
• 4 Prasad GV, Chiu R, Nash MM. et al. Statin use and bone mineral density in renal transplant recipients. Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg 2003; 3: 1320-1321
• 5 Solomon DH, Finkelstein JS, Wang PS. et al. Statin lipid-lowering drugs and bone mineral density. Pharmacoepidemiol Drug Saf 2005; 14: 219-226
• 6 Leutner M, Matzhold C, Bellach L. et al. Diagnosis of osteoporosis in statin-treated patients is dose-dependent. Ann Rheum Dis 2019; 78: 1706-1711
• 7 Kim SY, Yoo DM, Min C. et al. Association between osteoporosis and previous statin use: a nested case-control study. Int J Environ Res Public Health 2021; 18: 11902
• 8 Chung YS, Lee MD, Lee SK. et al. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 2000; 85: 1137-1142
• 9 Wada Y, Nakamura Y, Koshiyama H. Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes. Arch Intern Med 2000; 160: 2865
• 10 Huo G, Yin H. Relationship between statin drugs and bone density: a drug target-mediated Mendelian randomization study. Asian J Surg 2024; 48: 1185-1186
• 11 Ren Z, Zhou L. Association of statin use with osteoporosis risk: a drug-targeted Mendelian randomization study. Inflammopharmacology 2024; 32: 1253-1261
• 12 Cummings SR, San J, Martin MR. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-765
• 13 Cosman F, Crittenden DB, Adachi JD. et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 2016; 375: 1532-1543
• 14 Saag KG, Petersen J, Brandi ML. et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 2017; 377: 1417-1427
• 15 Miller PD, Hattersley G, Riis BJ. et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 2016; 316: 722-733
• 16 Bone HG, Cosman F, Miller PD. et al. ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab 2018; 103: 2949-2957
• 17 Adler RA, El-Hajj G, Fuleihan DC. et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2016; 31: 16-35
• 18 Bone HG, Bolognese MA, Yuen CK. et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 2011; 96: 972-980
• 19 Ginsberg C. Diagnosis and management of osteoporosis in advanced kidney disease: a review. Am J Kidney Dis 2022; 79: 427-436
• 20 Vasikaran SD, Miura M, Pikner R. et al. Practical considerations for the clinical application of bone turnover markers in osteoporosis. Calcif Tissue Int 2023; 112: 148-157
• 21 Jørgensen HS, Behets G, Viaene L. et al. Diagnostic accuracy of noninvasive bone turnover markers in renal osteodystrophy. Am J Kidney Dis 2022; 79: 667-676.e1
• 22 Fusaro M, Barbuto S, Gallieni M. et al. Real-world usage of Chronic Kidney Disease – Mineral Bone Disorder (CKD-MBD) biomarkers in nephrology practices. Clin Kidney J 2024; 17: sfad290
• 23 Jørgensen HS, Behets G, Bammens B. et al. Natural history of bone disease following kidney transplantation. J Am Soc Nephrol 2022; 33: 638-652
• 24 Jørgensen HS, Claes K, Smout D. et al. Associations of changes in bone turnover markers with change in bone mineral density in kidney transplant patients. Clin J Am Soc Nephrol 2024; 19: 483-493